Publications by authors named "Junya Ohtake"

Claim this Profile
R
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Junya Ohtake

Cancer Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
Rintaro Ono, Miho Ashiarai, Shinsuke Hirabayashi, Kazuyoshi Mizuki, Yosuke Hosoya, Junya Ohtake

Int J Hematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Norikazu Matsuo, Koichi Azuma, Satoshi Hattori, Junya Ohtake, Akihiko Kawahara

Int J Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.
Susumu Iiizumi, Junya Ohtake, Naoko Murakami, Taku Kouro, Mamoru Kawahara

Cancers (Basel)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Translational Research in Immuno-Oncology - Comprehensive Analysis of Phenotypes and Functions of Various Immune Cells Using the Colorectal Cancer Surgical Sample].
Junya Ohtake, Keisuke Kazama, Manabu Shiozawa, Tetsuro Sasada

Gan To Kagaku Ryoho· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Hidemitsu Kitamura, Yosuke Ohno, Yujiro Toyoshima, Junya Ohtake, Shigenori Homma

Cancer Sci· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are peptide vaccines viable in combination with other cancer immunotherapies?
Junya Ohtake, Tetsuro Sasada

Future Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status and future prospects of peptide-based cancer vaccines.
Satoshi Wada, Erika Yada, Junya Ohtake, Yuki Fujimoto, Hidemi Uchiyama

Immunotherapy· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment.
Tetsuro Sasada, Koichi Azuma, Junya Ohtake, Yuki Fujimoto

Front Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
Yosuke Ohno, Hidemitsu Kitamura, Norihiko Takahashi, Junya Ohtake, Shun Kaneumi

Cancer Immunol Immunother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells.
Junya Ohtake, Shun Kaneumi, Mishie Tanino, Takuto Kishikawa, Satoshi Terada

J Allergy Clin Immunol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway.
Kentaro Sumida, Yosuke Ohno, Junya Ohtake, Shun Kaneumi, Takuto Kishikawa

Sci Rep· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells.
Yasuo Shiohama, Junya Ohtake, Takayuki Ohkuri, Daisuke Noguchi, Yuji Togashi

Immunol Lett· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Junya Ohtake, Takayuki Ohkuri, Yuji Togashi, Hidemitsu Kitamura, Kiyotaka Okuno

Immunol Lett· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
Kazue Watanabe, Shingo Toji, Junya Ohtake, Kiichiroh Nakano, Takayuki Satoh

Biomed Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.
Norihiko Takahashi, Takayuki Ohkuri, Shigenori Homma, Junya Ohtake, Daiko Wakita

Cancer Sci· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis